Prevnar News and Research

RSS
Study highlights impact of government vaccine recommendations and direct-to-consumer pharmaceutical advertising

Study highlights impact of government vaccine recommendations and direct-to-consumer pharmaceutical advertising

New technology can provide immunization against infectious diseases

New technology can provide immunization against infectious diseases

Time to discuss potentially unpleasant side effects of COVID shots? Scientists say yes.

Time to discuss potentially unpleasant side effects of COVID shots? Scientists say yes.

Vaccine reduces race-based pneumococcal disease disparities

Vaccine reduces race-based pneumococcal disease disparities

Recommending adults to get pneumococcal vaccine at age 50 may be effective guidance

Recommending adults to get pneumococcal vaccine at age 50 may be effective guidance

The ratcheting cost of the pneumococcal vaccine: What gives?

The ratcheting cost of the pneumococcal vaccine: What gives?

New vaccine for pneumonia holds promise to save thousands of lives

New vaccine for pneumonia holds promise to save thousands of lives

One-shot vaccine passes key preclinical test in newborn monkey models

One-shot vaccine passes key preclinical test in newborn monkey models

Important vaccines that should not be missed by adults, elders and pregnant women

Important vaccines that should not be missed by adults, elders and pregnant women

Medical advisory panel recommends new pneumonia vaccine for seniors

Medical advisory panel recommends new pneumonia vaccine for seniors

Prevalence of bacterial meningitis drops in the United States

Prevalence of bacterial meningitis drops in the United States

Astellas, ClearPath announce strategic partnership to develop vaccine for infectious diseases

Astellas, ClearPath announce strategic partnership to develop vaccine for infectious diseases

Genocea commences GEN-004 Phase 1 study to prevent pneumococcus infections

Genocea commences GEN-004 Phase 1 study to prevent pneumococcus infections

European Commission approves updated label of Prevenar 13 for high risk pneumococcal disease

European Commission approves updated label of Prevenar 13 for high risk pneumococcal disease

Infant vaccination against pneumonia helps protect elderly

Infant vaccination against pneumonia helps protect elderly

Pfizer's Prevenar 13 receives European approval to include adults for prevention of invasive disease

Pfizer's Prevenar 13 receives European approval to include adults for prevention of invasive disease

Pfizer reports that Prevenar 13 Phase 3 study meets all primary, secondary objectives

Pfizer reports that Prevenar 13 Phase 3 study meets all primary, secondary objectives

Results from Pfizer’s Prevnar 13 Phase 3 study on HIV

Results from Pfizer’s Prevnar 13 Phase 3 study on HIV

FDA approves Pfizer’s Prevnar 13 to prevent pneumococcal disease in older children, adolescents

FDA approves Pfizer’s Prevnar 13 to prevent pneumococcal disease in older children, adolescents

EC approves Pfizer’s Prevenar 13 to prevent pneumococcal disease

EC approves Pfizer’s Prevenar 13 to prevent pneumococcal disease

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.